Genentech shares results from phase 3 trial for MS treatment

Betsy Goodfellow | July 13, 2023 | News story | Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial 

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute subcutaneous injection for the treatment of patients with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

The trial met its primary and secondary endpoints and was shown to be non-inferior to Ocrevus given by intravenous (IV) infusion, measured by pharmacokinetics over a 12-week period. The drug was also comparable to Ocrevus IV in controlling the magnetic resonance imaging (MRI) lesion activity in the brain throughout the same 12-week period. The safety profile of the drug remains consistent with IV administration.

Detailed results from the trial are expected to be presented at an upcoming medical meeting and will subsequently be submitted to the relevant global health authorities.

Levi Garraway, MD PhD, Genentech’s chief medical officer and head of Global Product Development, commented: “These results give people living with MS the possibility to receive the transformational benefits of Ocrevus in the way best suited to their lives while freeing up time and healthcare resources. This new subcutaneous injection will allow Ocrevus to be administered in ten minutes twice a year, helping people living with MS to spend less time in treatment for this disease.”

Betsy Goodfellow

Related Content

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …


Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

Latest content